<?xml version="1.0" encoding="UTF-8"?>
<p>Given the inherit limitations of these currently approved compounds and the potential risk for the arising of antiviral resistance, there is still an urgent need for developing new anti-influenza drugs. These novel drugs should have some (ideally all) of the following characteristics: effective when delivered late in infection, low propensity for developing antiviral resistance, broad activity (influenza A and B), improved effectiveness compared to the standard of care, and can be easily administered in uncomplicated as well as complicated cases of influenza (
 <xref rid="ref84" ref-type="bibr">Koszalka et al., 2017</xref>; 
 <xref rid="ref129" ref-type="bibr">Shaw, 2017</xref>). Next, we will summarize the most advanced (phase 2 and 3 clinical trials), promising drug candidates.
</p>
